Drugs / F18-3F4AP
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06999434 | May 2025 → May 2030 expected | Alzheimer disease, multiple sclerosis, radiculopathy, spinal cord injury | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT04699747 | Mar 2021 → Nov 2026 expected | multiple sclerosis | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04710550 | Jan 2021 → Dec 2025 | Alzheimer disease, demyelinating disease, traumatic brain injury | Massachusetts General Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F18-3F4AP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04710550 ↗ |
| Known as | [(18)F]3F4AP | “Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).” NCT04699747 ↗2“Common anesthetic used in preclinical PET imaging inhibits metabolism of the PET tracer [(18)F]3F4AP.” PMID 38690718 ↗ May 2024 |
| Modality | Diagnostic / imaging agent | “a novel positron emission tomography (PET) tracer” PMID 40759830 ↗ Aug 2025 |
| Route | Intravenous | “rapid intravenous bolus” NCT04699747 ↗ |